Telaprevir-related dermatitis

JAMA Dermatology

Volumn 149, Issue 2, 2013, Pages 152-158

  Roujeau, Jean Claude ^a   Mockenhaupt, Maja ^b   Tahan, Steven R ^c   Henshaw, Joshua ^d   Martin, Emily C ^d   Harding, Matt ^d   Van Baelen, Ben ^e   Bengtsson, Leif ^d   Singhal, Priya ^d   Kauffman, Robert S ^d   Stern, Robert S ^c  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b UNIVERSITY OF FREIBURG   (Germany)

^c HARVARD MEDICAL SCHOOL   (United States)

^d VERTEX PHARMACEUTICALS   (United States)

^e JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; PEGINTERFERON; PLACEBO; RIBAVIRIN; TELAPREVIR;

ARTICLE; BIOPSY; DERMATITIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRESS SYNDROME; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HEREDITY; HUMAN; INCIDENCE; MORPHOLOGY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RASH; RISK FACTOR; STEVENS JOHNSON SYNDROME; TREATMENT DURATION;

ADULT; ANTIVIRAL AGENTS; DRUG ERUPTIONS; FEMALE; HEPATITIS C; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OLIGOPEPTIDES; SEVERITY OF ILLNESS INDEX; STEVENS-JOHNSON SYNDROME;

EID: 84874230878     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.938     Document Type: Article

References (33)

1. McHutchison JG, Gordon SC, Schiff ER, et al Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339(21):1485-1492.
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-965.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-982.
4. Lübbe J, Kerl K, Negro F, Saurat JH. Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases. Br J Dermatol. 2005;153(5):1088-1090.
5. Charron A, Bessis D, Dereure O, Guilhou JJ, Guillot B. Local cutaneous side effects of interferons. Presse Med. 2001;30(31, pt 1):1555-1560.
6. Mistry N, Shapero J, Crawford RI. A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol. 2009; 23(10):677-683.
7. Dereure O, Raison-Peyron N, Larrey D, Blanc F, Guilhou JJ. Diffuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol. 2002;147(6):1142-1146.
8. Savk E, Uslu G, Karaoǧlu AO, Sendur N, Karaman G. Diffuse cutaneous eruption due to interferon alfa and ribavirin treatment of chronic hepatitis C. J Eur Acad Dermatol Venereol. 2005;19(3):396-398.
9. Hashimoto Y, Kanto H, Itoh M. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus. J Dermatol. 2007;34(8):577-582.
10. Veluru C, Atluri D, Chadalavada R, Burns E, Mullen KD. Skin rash during chronic hepatitis C therapy. Gastroenterol Hepatol (N Y). 2010;6(5):323-325.
11. McHutchison JG, Everson GT, Gordon SC, et al; PROVE1 Study Team. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl JMed. 2009; 360(18):1827-1838.
12. published correction appears in N Engl JMed. 2009;361:1516
13. Hézode C, Forestier N, Dusheiko G, et al; PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360(18):1839-1850.
14. McHutchison JG, Manns MP, Muir AJ, et al; PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362(14):1292- 1303.
15. published correction appears in N Engl J Med. 2010;362:1647
16. Muir AJ, Poordad FF, McHutchison JG, et al. Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. Hepatology. 2011;54(5):1538-1546.
17. Jacobson IM, McHutchison JG, Dusheiko G, et al ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-2416.
18. Sherman KE, Flamm SL, Afdhal NH, et al ILLUMINATE Study Team. Responseguided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365 (11):1014-1024.
19. published correction appears in N Engl J Med. 2011;365:1551.
20. Zeuzem S, Andreone P, Pol S, et al REALIZE Study Team. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417-2428.
21. Fung KL, Gottesman MMA. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta. 2009;1794 (5):860-871.
22. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics. 2003;4(4):397-410.
23. Johne A, Köpke K, Gerloff T, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther. 2002; 72(5):584-594.
24. MedDRA MSSO. Medical Dictionary for Regulatory Activities Maintenance and Support Services Organization. http://www.meddramsso.com/index.asp. Accessed June 28, 2011.
25. Ludbrook J. Multiple comparison procedures updated. Clin Exp Pharmacol Physiol. 1998;25(12):1032-1037.
26. The RegiScar Project. European Registry of Severe Cutaneous Adverse Reactions (SCAR) to Drugs and Collection of Biological Samples. http://regiscar .uni-freiburg.de/. Accessed June 28, 2011.
27. Montaudié H, Passeron T, Cardot-Leccia N, Sebbag N, Lacour JP. Drug rash with eosinophilia and systemic symptoms due to telaprevir. Dermatology. 2010; 221(4):303-305.
28. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359(9308):727-732.
29. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens- Johnson syndrome. Nature. 2004;428(6982):486.
30. Chen ST, Wu PA. Severe cutaneous eruptions on telaprevir. J Hepatol. 2012;57(2): 470-472.
31. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15 438 consecutive inpatients, 1975 to 1982. JAMA. 1986;256(24):3358-3363.
32. Dupin N, Mallet V, Carlotti A, Vallet-Pichard A, Pol S. Severe skin rash in case of readministration of telaprevir in a patient who previously experienced a non severe rash. Hepatology. 2012;55(6):2042-2043.
33. Bachot N, Roujeau J-C. Differential diagnosis of severe cutaneous drug eruptions. Am J Clin Dermatol. 2003;4(8):561-572.